Arbutus Biopharma

Yahoo Finance • 3 days ago

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026 FDA... Full story

Yahoo Finance • 14 days ago

Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway.

Moderna defied expectations of a Covid-revenue slowdown on Friday as a surge in international vaccine sales underpinned its first-quarter results. Revenue more than tripled in Moderna’s latest quarter to $389 million from $108 million last... Full story

Yahoo Finance • 29 days ago

Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability

We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Arbutus Biopharma Corporation is among the best biotech stocks under $10 to buy. TheFly reported on April 7 that Jefferies lowered its price target on ABUS from $... Full story

Yahoo Finance • 2 months ago

Moderna to pay up to $2.25B to settle COVID vaccine patent matter

Moderna to pay up to $2.25B to settle COVID vaccine patent matter Proactive uses images sourced from Shutterstock Moderna Inc (NASDAQ:MRNA, XETRA:0QF) stock added almost 9% after it was announced that the drugmaker has agreed to pay up to... Full story

Yahoo Finance • 2 months ago

Moderna gains as Arbutus/ Genevant settlement removes major financial risk

[Massachusetts Based Biotech Company Moderna Receives FDA Approval To Continue Coronavirus Vaccine Trials] Maddie Meyer/Getty Images News Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) shares continued to rise in the premarket on W... Full story

Yahoo Finance • 2 months ago

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

March 4 (Reuters) - Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the ‌technology that made its COVID-19 vaccine possible, removing an overhang and ‌allowing it to focu... Full story

Yahoo Finance • 2 months ago

Moderna Just Settled a Lawsuit. What It Means for the Stock.

The company settles to resove patent litigation related to its Covid-19 vaccine, removing an overhang for shares. Continue Reading... Full story

Yahoo Finance • 2 months ago

Stocks to Watch Wednesday: CrowdStrike, Gitlab, Moderna, Strategy

↘️ GitLab (GLTB): The software-development tools company said it expects slower annual sales growth, stoking concerns around the threat artificial intelligence poses for the sector. Shares fell 9% in premarket trading. Continue Reading... Full story

Yahoo Finance • 2 months ago

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Arbutus Biopharma Corporation Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized, this se... Full story

Yahoo Finance • 2 months ago

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

Roivant Sciences Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized, this settlement will... Full story

Yahoo Finance • 3 months ago

Moderna faces $5 billion mRNA patent lawsuit after 'Star Trek' ruling

Behind the household COVID-19 name, Moderna, is facing a $5 billion patent-infringement lawsuit over vaccine technology. On February 2, 2026, U.S. District Judge Joshua D. Wolson denied Moderna’s request for summary judgment, saying the j... Full story

Yahoo Finance • 3 months ago

Arbutus jumps on ruling in patent dispute with Moderna

[Vaccine patent file folder] oonal/iStock via Getty Images * Arbutus Biopharma (ABUS [https://seekingalpha.com/symbol/ABUS]) is up ~10% in Monday afternoon trading after a federal judge in Delaware determined that a patent dispute invol... Full story

Yahoo Finance • 6 months ago

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025... Full story

Yahoo Finance • 9 months ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssenjoi... Full story

Yahoo Finance • 11 months ago

Arbutus Biopharma Reacquires China Rights To Imdusiran

(RTTNews) - Arbutus Biopharma (ABUS) has reacquired China rights to its lead compound, imdusiran, from Qilu Pharmaceutical, a pharmaceutical company in China. The companies have mutually agreed to conclude the strategic partnership entered... Full story

Yahoo Finance • 11 months ago

Arbutus reacquires China rights to imdusiran after Qilu partnership ends

WARMINSTER, Pa. - Arbutus Biopharma Corporation (NASDAQ:ABUS), currently valued at $645 million, has regained full global rights to its lead hepatitis B compound imdusiran after mutually agreeing with Qilu Pharmaceutical to end their strat... Full story

Yahoo Finance • 11 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa... Full story

Yahoo Finance • last year

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral P... Full story

Yahoo Finance • last year

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infect... Full story

Yahoo Finance • last year

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development... Full story